Method for treating multi-drug resistant tumors

Details Method for treating multi-drug resistant tumors Method for treating multi-drug resistant tumors

2007-12-04

2007-12-04

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C514S506000, C514S767000, C514S768000, C554S078000, C554S080000, C554S081000, C554S085000, C564S503000

Reexamination Certificate

active

10714085

ABSTRACT:
Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug conjugate, where the drug is linked to a hydrophobic moiety, such as a lipid, through a cleavable dithiobenzyl linkage. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of mitomycin C in its original form. The linkage is stable under nonreducing conditions. The prodrug conjugate can be incorporated into liposomes for administration in vivo and release of mitomycin C in response to endogenous in vivo reducing conditions or in response to administration of an exogenous reducing agent.

REFERENCES:
patent: 4021449 (1977-05-01), Fujimoto et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 4935465 (1990-06-01), Garman
patent: 5103556 (1992-04-01), Filip et al.
patent: 5395619 (1995-03-01), Zalipsky et al.
patent: 5560923 (1996-10-01), Rahman et al.
patent: 5631018 (1997-05-01), Zalipsky et al.
patent: 5648090 (1997-07-01), Rahman et al.
patent: 5891468 (1999-04-01), Martin et al.
patent: 6180095 (2001-01-01), Greenwald et al.
patent: 6342244 (2002-01-01), Zalipsky
patent: 6365179 (2002-04-01), Zalipsky et al.
patent: 6605299 (2003-08-01), Zalipsky
patent: 6638500 (2003-10-01), El-Tayar et al.
patent: 6849270 (2005-02-01), Zalipsky
patent: 6984396 (2006-01-01), Zalipsky et al.
patent: 2004/0161455 (2004-08-01), Gabizon et al.
patent: 2004/0213579 (2004-10-01), Zalipsky et al.
patent: 0 317 956 (1989-05-01), None
patent: 0 317 957 (1989-05-01), None
patent: 0 317 957 (1989-05-01), None
patent: 0 510 197 (1992-10-01), None
patent: 0 898 968 (1999-03-01), None
patent: 2 254 336 (1975-07-01), None
patent: 1113391 (1989-05-01), None
patent: WO 9736904 (1997-10-01), None
patent: WO 98/16201 (1998-04-01), None
patent: WO 99/29302 (1999-06-01), None
patent: WO00/64483 (2000-11-01), None
patent: WO 00/64484 (2000-11-01), None
patent: WO00/64484 (2000-11-01), None
patent: WO01/26629 (2001-04-01), None
patent: WO02/26265 (2002-04-01), None
patent: WO03/053409 (2003-07-01), None
patent: WO2004/110497 (2004-12-01), None
Thierry, A.R. et al in FASEB J. vol. 6, pp. 572-579, 1993.
Warren et al in Cancer Research, vol. 52, 3241-3245, 1992.
Ellman, G.I., Arch. Biochem. Biophys., 82:70-77 (1959).
Grassetti and Murray, Arch. Biochem. Biophys., 119(1):41-49 (1967).
Brois, S.J., et al.,J. Amer. Chem. Soc. 92(26):7629-7631 (1970).
Dittmer, J.C., et al.,J. Lipid Res.126-127 (1964).
Gaber, M., et al.,Pharmaceutical Res 12(10):1407-1416, (1995).
Grice, R., et al.,J. Chem. Soc.1947-1954 (1963).
Hirota, S.,International J of Pharmaceutics 162(1-2):185-194, (1998).
Engman, L., et al., Bioorganic & Medicinal Chemistry 11:5091-5100, (2003).
Johnsson, M., et al.,J of Liposome Res 9(1):53-79, (1999).
Kaneko, T., et al.,Bioconjugate Chem. 2(3):133-141 (1991).
Kirpotin, D., et al.,FEBS Letters 388:115-118, (1996).
Lash, L.H., et al.,Arch. Biochem. Biophys. 240(2):583-592 (1985).
Mueller, C.E., et al., 322(6):343-350, (1989).
Senter, P.D., et al.,J Org Chem 55(9):2975-2978, (1990).
Vaage, J., et al.,Cancer 72(12):3671-3675, (1993).
Vaage, J., et al.,Cancer 73(5):1478-1484, (1994).
Vaage, J., et al.,International J of Cancer 51(6)942-948, ().
Veronese, et al.,Applied Biochem. and Biotech.141-152 (1985).
Zalipsky, et al.,Biotechnol. Appl. Biochem.100-114 (1992).
Zalipsky, et al.,Eur. Polymer. J. 19(12):1177-1183 (1983).
Zalipsky, et al.,Bioconj. Chem. 4(4):296-299 (1993).
Zalipsky,Bioconj Chem 10(5):703-707, (1999).
Vaage, J., et al.,Int. J. Cancer(80): 134-137(1999).
Asai et al.,Biol. Pharm. Bull., 21(7):766-771 (1998).
Briddell et al.,Blood, 102(11):163b-164b (1999).
Database Dissertation Abstracts [Online] Proquest Info & Learning; Woghiren, Clement O. et al.: “Synthesis, Characterization and Conjugation of a Novel Protected Thiol-Polyethylene Glycol: A New Activated Polymer for Reversible Protein Modification (IL-2)” Dialog Accession No. 01367093; Dissertation Abstracts 55(03-B), 1994, p. 866.
Johnson et al.,Chemistry and Biology, 4(12):939-950 (1997).
Kratz et al.,J. Med. Chemistry, 45(12):5523-5533 (2002).
Malik et al.,Experimental Hematology, 28(7, Suppl. 1):106, Abstract No. 237 (2000).
Thorpe et al.,Cancer Res., 47(12):5924-5931 (1987).
Vaage et al.,International Journal of Cancer, 80(1):134-137 (1999).
Worrell et al.,Anticancer Drug Design, 1(12):179-188 (1986).
Diaz, et al.,Bioconjugate Chem 9:250-254, (1998).
Vaage, J., et al.,Intl J Cancer 51(6):942-948, (1992).
Zalipsky, S., et al., 28thInternational Symposium on Controlled Release of Bioactive Materials and 4thConsumer & Diversified Products Conference, San Diego, CA, Publisher: Controlled Release Society 1:437-438, (2001).

Affiliated with

Also associated with

Rating

Method for treating multi-drug resistant tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for treating multi-drug resistant tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating multi-drug resistant tumors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3833307